Presence of B cells in tertiary lymphoid structures is associated with a protective immunity in patients with lung cancer

American Journal of Respiratory and Critical Care Medicine

Volumn 189, Issue 7, 2014, Pages 832-844

  Germain, Claire ^a,b,c   Gnjatic, Sacha ^d,e   Tamzalit, Fella ^a,b,c   Knockaert, Samantha ^a,b,c   Remark, Romain ^a,b,c   Goc, Jérémy ^a,b,c   Lepelley, Alice ^a,b,c   Becht, Etienne ^a,b,c   Katsahian, Sandrine ^a,f   Bizouard, Geoffray ^f   Validire, Pierre ^a,g   Damotte, Diane ^a,b,c,h   Alifano, Marco ^h   Magdeleinat, Pierre ^g,h   Cremer, Isabelle ^a,b,c   Teillaud, Jean Luc ^a,b,c   Fridman, Wolf Herman ^a,b,c,i   Sautès Fridman, Catherine ^a,b,c   Dieu Nosjean, Marie Caroline ^a,b,c  

^a CENTRE DE RECHERCHE DES CORDELIERS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d IcahnSchool of Medicine at Mount Sinai   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f HENRI MONDOR HOSPITAL   (France)

^g INSTITUT MUTUALISTE MONTSOURIS   (France)

^h HÔTEL DIEU   (France)

ⁱ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

Author keywords

Antibody; Follicular B cell; Non small cell lung cancer; Prognostic marker; Tumor immunology

Indexed keywords

ANTINEOPLASTIC AGENT; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL COMPOSITION; CELL DENSITY; CELL DIFFERENTIATION; CELL MATURATION; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; EARLY CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GERMINAL CENTER; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LONG TERM SURVIVAL; LUNG NON SMALL CELL CANCER; LYMPHOID ORGAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PLASMA CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOMATIC HYPERMUTATION; TERTIARY LYMPHOID STRUCTURE; TUMOR IMMUNITY;

B-LYMPHOCYTE SUBSETS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, HUMORAL; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 84897391372     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201309-1611OC     Document Type: Article

References (52)

1. Hamaï A, Duperrier-Amouriaux K, Pignon P, Raimbaud I, Memeo L, Colarossi C, Canzonieri V, Perin T, Classe J-M, Campone M, et al. Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS ONE 2011; 6: e21129.
2. Redjimi N, Duperrier-Amouriaux K, Raimbaud I., Luescher I, Dojcinovic D, Classe J-M, Berton-Rigaud D, Frenel J-S, Bourbouloux E, Valmori D, et al. NY-ESO-1-specific circulating CD41 T cells in ovarian cancer patients are prevalently TH1 type cells undetectable in the CD251FOXP31Treg compartment. PLoS ONE 2011; 6:e22845.
3. Ohue Y, Eikawa S, Okazaki N., Mizote Y, Isobe M, Uenaka A., Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer 2012; 131:E649-E658.
4. Zippelius A, Gati A, Bartnick T., Walton S, Odermatt B, Jaeger E., Dummer R, Urosevic M, Filonenko V, Osanai K, et al. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother 2007; 56:249-258.
5. Walton SM, Gerlinger M, de la Rosa O, Nuber N, Knights A, Gati A, Laumer M, Strauss L, Exner C, Schäfer N, et al. Spontaneous CD8 T cell responses against the melanocyte differentiation antigen RAB38/NY-MEL-1 in melanoma patients. J Immuno. 2006; 177: 8212-8218.
6. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000; 60:1777-1788.
7. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
8. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306.
9. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A., Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964.
10. Erdag G, Schaefer JT, Smolkin M.E., Deacon DH, Shea SM, Dengel LT, Patterson J.W., Slingluff CL Jr. Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res 2012; 72: 1070-1080.
11. Nelson BH. CD201 B cells: the other tumor-infiltrating lymphocytes. J Immuno. 2010; 185:4977-4982.
12. Rodríguez-Pinto D. B cells as antigen presenting cells. Cell Immuno. 2005; 238:67-75.
13. DeNardo DG, Coussens LM Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 2007; 9:212.
14. Barbera-Guillem E., Nelson MB, Barr B, Nyhus J.K., May KF Jr, Feng L, Sampsel JW Blymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion. Cancer Immunol Immunother 2000; 48:541-549.
15. DiLillo DJ, Yanaba K, Tedder TF B cells are required for optimal CD41 and CD81 T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immuno. 2010; 184: 4006-4016.
16. Tan T-T, Coussens LM Humoral immunity, inflammation and cancer. Curr Opin Immuno. 2007; 19:209-216.
17. Barbera-Guillem E., May KF Jr, Nyhus JK, Nelson MB Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by anti-tumor antibodies. Neoplasia 1999; 1:453-460.
18. Ammirante M, Luo J-L, Grivennikov S, Nedospasov S., Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464:302-305.
19. DeNardo DG, Andreu P, Coussens LM Interactions between lymphocytes and myeloid cells regulate pro-versus anti-tumor immunity. Cancer Metastasis Rev 2010; 29:309-316.
20. Simsa P, Teillaud J-L, Stott DI, Tóth J, Kotlan B. Tumor-infiltrating B cell immunoglobulin variable region gene usage in invasive ductal breast carcinoma. Pathol Oncol Res 2005; 11:92-97.
21. Kotlan B, Simsa P, Teillaud J-L, Fridman WH, Toth J, McKnight M., Glassy MC. Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: the proof of principle concerning the tumor-infiltrating B lymphocytes. J Immuno. 2005; 175:2278-2285.
22. Schmidt M, Böhm D, von Torne C, Steiner E, Puhl A., Pilch H, Lehr H-A, Hengstler JG, Kölbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008; 68:5405-5413.
23. Dieu-Nosjean M-C, Antoine M, Danel C, Heudes D, Wislez M, Poulot V, Rabbe N, Laurans L, Tartour E, de Chaisemartin L, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 2008; 26:4410-4417.
24. Drayton DL, Liao S, Mounzer R.H., Ruddle NH Lymphoid organ development: from ontogeny to neogenesis. Nat Immuno. 2006; 7: 344-353.
25. Neyt K, Perros F, GeurtsvanKessel C.H., Hammad H., Lambrecht BN Tertiary lymphoid organs in infection and autoimmunity. Trends Immuno. 2012; 33:297-305.
26. Moyron-Quiroz J.E., Rangel-Moreno J, Kusser K., Hartson L, Sprague F, Goodrich S., Woodland DL, Lund FE, Randall TD. Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity. Nat Med 2004; 10:927-934.
27. Germain C, Tamzalit F, Knockaert S., Gnjatic S, Validire P, Remark R., Damotte D, Fridman WH, Sautes-Fridman C, Dieu-Nosjean MC, et al. Intra-tumoral B cells are able to organize into tertiary lymphoid structures and to develop a protective humoral immune response in lung cancer patients. Presented at the 15th International Congress of Immunology, Milan, Italy, August 22-27, 2013.
28. de Chaisemartin L., Goc J, Damotte D., Validire P, Magdeleinat P, Alifano M., Cremer I, Fridman W-H, Sautès-Fridman C, Dieu-Nosjean M-C. Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. Cancer Res 2011; 71:6391-6399.
29. Gnjatic S, Old LJ, Chen Y-T. Autoantibodies against cancer antigens. Methods Mol Biol 2009; 520:11-19.
30. Remark R, Alifano M, Cremer I., Lupo A, Dieu-Nosjean M-C, Riquet M, Crozet L, Ouakrim H, Goc J, Cazes A, et al. Characteristics and clinical impacts of the immune environments in colorectal and renal cell carcinoma lung metastases: influence of tumor origin. Clin Cancer Res 2013; 19:4079-4091.
31. Altman DG, Lausen B, Sauerbrei W., Schumacher M. Dangers of using "optimal," cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994; 86:829-835.
32. van de Pavert SA, Mebius RE New insights into the development of lymphoid tissues. Nat Rev Immuno. 2010; 10:664-674.
33. Riley JK, Sliwkowski MX CD20: a gene in search of a function. Semin Oncol 2000; 27(6, Suppl 12)17-24.
34. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994; 180:329-339.
35. Caraux A, Klein B, Paiva B., Bret C, Schmitz A, Fuhler G.M., Bos NA, Johnsen HE, Orfao A, Perez-Andres M; Myeloma Stem Cell Network. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138- and CD138+ plasma cells. Haematologica 2010; 95:1016-1020.
36. Stockert E, Jäger E, Chen Y-T, Scanlan MJ, Gout I, Karbach J., Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187:1349-1354.
37. Gnjatic S, Ritter E, Büchler MW, Giese N.A., Brors B., Frei C, Murray A, Halama N., Zornig I, Chen Y-T, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010; 107:5088-5093.
38. Bindea G, Mlecnik B, Tosolini M., Kirilovsky A, Waldner M, Obenauf A.C., Angell H., Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-795.
39. Gatto D, Brink R. The germinal center reaction. J Allergy Clin Immunol 2010; 126:898-907, quiz 908-909.
40. Al-Shibli K.I., Donnem T, Al-Saad S, Persson M., Bremnes RM, Busund L-T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008; 14:5220-5227.
41. LadA & Acute;nyi A, Kiss J, Mohos A, Somlai B, Liszkay G, Gilde K, Fejös Z, Gaudi I, Dobos J, TímA & Acute;r J. Prognostic impact of B-cell density in cutaneous melanoma. Cancer Immunol Immunother 2011; 60: 1729-1738.
42. Mahmoud SMA, Lee AHS, Paish EC, Macmillan R.D., Ellis IO, Green AR. The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012; 132:545-553.
43. + follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest 2013; 123:2873-2892.
44. Goc J, Germain C, Vo-Bourgais TKD, Lupo A, Klein C., Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, et al. Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the good positive prognostic value of infiltrating CD81 T cells. Cancer Res 2014; 74: 705-715.
45. Nielsen JS, Sahota RA, Milne K, Kost S.E., Nesslinger NJ, Watson PH, Nelson BH CD201 tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD81 T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res 2012; 18: 3281-3292.
46. Ayyoub M, Taub RN, Keohan M-L, Hesdorffer M, Metthez G., Memeo L, Mansukhani M, Hibshoosh H, Hesdorffer CS, Valmori D. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4:7.
47. Cipponi A, Mercier M, Seremet T., Baurain J-F, TheA & Acute;te I, van den Oord J, Stas M, Boon T, Coulie PG, van Baren N. Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. Cancer Res 2012; 72:3997-4007.
48. Lohr M, Edlund K, Botling J., Hammad S, Hellwig B, Othman A., Berglund A, Lambe M, Holmberg L, Ekman S, et al. The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer. Cancer Lett 2013; 333:222-228.
49. Jäger E, Karbach J, Gnjatic S, Neumann A, Bender A, Valmori D, Ayyoub M, Ritter E, Ritter G, Jäger D, et al. Recombinant vaccinia/ fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci USA 2006; 103:14453-14458.
50. Bioley G, Guillaume P, Luescher I., Bhardwaj N, Mears G, Old L., Valmori D, Ayyoub M. Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing tumors. J Immunother 2009; 32:161-168.
51. Noguchi T, Kato T, Wang L., Maeda Y, Ikeda H, Sato E., Knuth A, Gnjatic S, Ritter G, Sakaguchi S, et al. Intracellular tumor-associated antigens represent effective targets for passive immunotherapy. Cancer Res 2012; 72:1672-1682.
52. Kalergis AM, Ravetch JV Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells. J Exp Med 2002; 195:1653-1659.